Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying ...

MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...

Ultrasensitive detection of circulating tumor DNA can improve clinical outcomes in aggressive B-cell lymphomas by identifying measurable residual disease. Defining remission is challenging due to ...

Co., Inc. (NYSE: MRK) has initiated a pivotal Phase 3 clinical trial, waveLINE-010, to evaluate the efficacy of its investigational drug zilovertamab vedotin in treating patients with previously ...

Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, highlights the role of bispecific antibodies in lymphoma research.

A protein called B cell lymphoma 6 could be key to maintaining healthy muscle mass and potentially could be used to combat ...

Northwestern Medicine scientists have uncovered a key pathway controlling tumor growth in B-cell lymphomas, according to a ...

Disparate pathogenic mechanisms complicate precision-medicine efforts to treat diffuse large B-cell lymphoma (DLBCL), the most common lymphoma diagnosis. Though potentially curable with frontline ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

The committee reviewed data showing a 94 percent complete response rate as a third- or later-line treatment for refractory follicular lymphoma.

Cancer survivor Zoe Plastiras hopes her message provides some reassurance by highlighting advances in cancer treatment.